Although sodium-glucose cotransporter 2 inhibitors (SGLT2is) were initially developed and approved by the US Food and Drug Administration (FDA) for the glycemic management of type 2 diabetes mellitus (DM2), their effect on cardiac and renal health has led to an expanded use in clinical practice. The gene discussed is SLC5A2; the disease is myotonic dystrophy type 2.